Nomowake 25 25 mg Tablet
PDF Leaflet Revision Date: 8 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Alleviation of insomnia.
Dosage (summary)
1-2 tablets at bedtime for adults over 12 years.
Onset of Action / Duration
Onset: 30 mins, Duration: 6-8 hours
Special Populations
- Elderly patients
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CNS depressants
- MAOIs
- QT prolonging medications
Contraindications
- Hypersensitivity to doxylamine
- Severe cardiovascular disorders
- Epilepsy
- Acute asthma attack
Common side effects
- Drowsiness
- Dry mouth
- Constipation
- Blurred vision
- Urinary retention
Counselling Points
- Avoid alcohol during treatment
- Do not operate machinery if drowsy
- Consult doctor if insomnia persists
Serious warnings
- Short treatment duration recommended
- Caution in elderly patients
- Risk of falls in elderly
Important Disclaimer
The Nomowake 25 25 mg Tablet professional information leaflet below is the property of Lebasi Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
